首页> 外文学位 >Polio is (still) not dead: Vaccine vectors, antiviral drugs, pathogenesis, and unexpected mutants.
【24h】

Polio is (still) not dead: Vaccine vectors, antiviral drugs, pathogenesis, and unexpected mutants.

机译:脊髓灰质炎还没有死:疫苗载体,抗病毒药物,发病机制和意外突变。

获取原文
获取原文并翻译 | 示例

摘要

The results presented here are divided among four projects: (I) candidate AIDS vaccine, (II) Ribavirin is an RNA virus mutagen, (III) Poliovirus receptor (PVR) transgenic mice, and (IV) Novel poliovirus mutants. In project I, we provide the first report of protection against a vaginal challenge with a highly virulent SIV using a vaccine vector. We constructed new poliovirus vaccine vectors using Sabin 1 and 2 vaccine strain viruses, from which we generated a series of SabRV-SIV viruses containing SIV (simian immunodeficiency virus) gag, pol, env, nef, and tat in overlapping fragments. Two cocktails of poliovirus vectors (SabRV1-SIV and SabRV2-SIV) were then inoculated in a prime-boost regimen to vaccinate seven macaques. All seven vaccinated macaques, and twelve control macaques, were then challenged vaginally with highly pathogenic uncloned SIVmac251. Strikingly, 4 of 7 vaccinated animals exhibited substantial protection against the vaginal SIV challenge. All twelve control monkeys became SIV+. These results demonstrate the efficacy of SabRV as a potential human vaccine vector to prevent AIDS, and that a vaccine vector cocktail expressing an array of defined antigenic sequences can be an effective vaccination strategy in an outbred population. In project II, we demonstrate that the important broad spectrum antiviral drug ribavirin (currently used to treat hepatitis C infections among others) is an RNA virus mutagen. We describe a molecular test of the error catastrophe theory and demonstrate that ribavirin's full antiviral activity is exerted through lethal mutagenesis of the viral genetic material. We conclude that mutagenic ribonucleosides may be an important new class of anti-RNA virus agents. In project III, we constructed a PVR transgenic mouse susceptible to a mucosal route of poliovirus infection. In project IV, we describe the discovery of two interesting independent sets of poliovirus mutants. One set of mutants contains novel manganese dependent RNA dependent RNA polymerases, and the other set of mutants is resistant to brefeldin A. Brefeldin A was the only anti-poliovirus compound for which no escape mutants were known. It has been presumed that the virus could not become resistant to brefeldin A because the drug targets a cellular host protein, not the virus directly.
机译:这里介绍的结果分为四个项目:(I)候选艾滋病疫苗,(II)利巴韦林是一种RNA病毒诱变剂,(III)脊髓灰质炎病毒受体(PVR)转基因小鼠,以及(IV)新型脊髓灰质炎病毒突变体。在项目I中,我们提供了使用疫苗载体针对高毒力SIV防止阴道攻击的第一份报告。我们使用Sabin 1和2疫苗株病毒构建了新的脊髓灰质炎病毒疫苗载体,从中我们产生了一系列SabRV-SIV病毒,其中包含重叠片段的SIV(猿猴免疫缺陷病毒)gag,pol,env,nef和tat。然后将两种脊髓灰质炎病毒载体混合物(SabRV1-SIV和SabRV2-SIV)接种至初免-加强方案中,以接种7只猕猴。然后用高病原性未克隆的SIV mac2 51对所有7只接种过的猕猴和12只对照猕猴进行阴道攻击。令人惊讶的是,在7只接种疫苗的动物中,有4只显示出对阴道SIV攻击的实质性保护。全部十二只对照猴子成为SIV + 。这些结果证明,SabRV作为预防AIDS的潜在人类疫苗载体的功效,并且表达一系列定义的抗原序列的疫苗载体混合物在远距离人群中可以是有效的疫苗接种策略。在项目II中,我们证明了重要的广谱抗病毒药物利巴韦林(目前用于治疗丙型肝炎等)是一种RNA病毒诱变剂。我们描述了错误突变理论的分子测试,并证明了利巴韦林的全部抗病毒活性是通过病毒遗传物质的致死诱变而发挥的。我们得出结论,诱变核糖核苷可能是一类重要的新型抗RNA病毒制剂。在项目III中,我们构建了对脊髓灰质炎病毒感染的粘膜途径敏感的PVR转基因小鼠。在项目IV中,我们描述了两个有趣的脊髓灰质炎病毒突变体的有趣独立集合的发现。一组突变体包含新颖的锰依赖性RNA依赖性RNA聚合酶,另一组突变体对布雷菲德菌素A具有抗性。布雷菲德菌素A是唯一未知的逃脱突变体的抗脊髓灰质炎病毒化合物。据推测,该病毒不能对布雷菲德菌素A产生抗性,因为该药靶向细胞宿主蛋白,而不是直接针对病毒。

著录项

  • 作者

    Crotty, Shane.;

  • 作者单位

    University of California, San Francisco.;

  • 授予单位 University of California, San Francisco.;
  • 学科 Biology Microbiology.; Health Sciences Immunology.; Biology Molecular.
  • 学位 Ph.D.
  • 年度 2001
  • 页码 438 p.
  • 总页数 438
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 微生物学;预防医学、卫生学;分子遗传学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号